George M. Rodgers, III,
MD, PhD
Languages Spoken: English
George M. Rodgers, M.D., Ph.D. is a Professor of Medicine in the Division of Hematology and Hematologic Malignancies, Department of Internal Medicine at the University of Utah School of Medicine. He also holds an appointment as an adjunct Professor in the Department of Pathology. He started at the University of Utah in 1988. He is the senior adult hemophilia and thrombosis expert in the state of Utah, and also serves as the adult hemophilia expert for - and receives referrals and consultations from - a six state region. His clinical practice is conducted at the University of Utah's Sugarhouse Clinic. Dr. Rodgers is also a Medical Director for the Coagulation Laboratory at ARUP Laboratories. He is the chairman of the University Hospital Adverse Drug Reaction Subcommittee. He is also a member of the University Hospital Pharmacy & Therapeutics, Department of Medicine Tenure 5-Year Review and the Heme-Onc Fellowship and Clinical Competency Committees. He is also a principal investigator for three clinical trials and the Director of the Utah Center for Bleeding and Clotting Disorders.
For questions regarding Dr. Rodgers' practice, our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist/New Patient Coordinator at www.huntsmancancer.org or (801) 587-4630.
Clinical Locations
Hematology Clinic
801-585-2626
St. George Specialty Clinic at Richens Eye Center
Hemophilia Outreach Clinic801-213-8301
801-581-2000
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Professor Pathology - Adjunct Professor |
| Academic Divisions | Clinical Pathology Hematology/BMT |
| Board Certification | American Board of Internal Medicine (Internal Medicine) American Board of Internal Medicine (Sub: Hematology) American Board of Pathology (Sub: Hematology) Federal Licensing Examination National Board of Medical Examiners |
Patient Rating
The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Likelihood of recommending care provider
4.5/ 5
Care provider's explanation of condition/problem
4.5/ 5
Care provider's effort to include me in decisions
4.5/ 5
Wait time at clinic
4.5/ 5
Care provider's concern for questions & worries
4.6/ 5
Patient Comments
Patient comments are gathered from our Press Ganey Patient Satisfaction Survery and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
UofU Patient
July 17, 2021
SUGAR HOUSE HEALTH CENTER
Good
UofU Patient
May 20, 2021
SUGAR HOUSE HEALTH CENTER
Dr. Rodgers is an incredible hematologist with excellent bedside manner. His nurse, Mia, and assistants Kara and Darryl are excellent just like Dr. Rodgers
UofU Patient
May 08, 2021
SUGAR HOUSE HEALTH CENTER
Excellent!
UofU Patient
April 15, 2021
SUGAR HOUSE HEALTH CENTER
He didn't listen. He wouldn't look up tests I had just recently done (I even gave him the exact date to make it easier) and made me redo all of the blood tests again. He wouldn't let me finish my sentences, so he still has no idea why I was there in the first place. He was anxious to move on and didn't give me the time of day . . .
UofU Patient
April 08, 2021
SUGAR HOUSE HEALTH CENTER
Dr Rogers was excellent! very professional + gave me good explanation of my treatment options.
UofU Patient
April 05, 2021
SUGAR HOUSE HEALTH CENTER
Good Game plan but haven't received the meds yet.
UofU Patient
March 18, 2021
SUGAR HOUSE HEALTH CENTER
Always willing to answered questions I had and finding out the answer for me. Very caring people
UofU Patient
February 13, 2021
SUGAR HOUSE HEALTH CENTER
Physician failed to appropriately acknowledge my complaint that records that I had directed the physician's office have available for physician to consider prior to visit had not been honored. I also later learned that those records were not sought, in contravention of my explicit pre-visit request, until after my visit, one week after my initial request. I also later learned that slides necessary for physician's review of my case were not ordered until 4 days after my visit and apparently not examined and reviewed for 10 days following my visit. In light of my voiced concern about the tardiness of his office in responding to my initial request and physician's unfulfilled promise that he would call me about the results of his colleagues review of the slides, I ultimately felt slighted. I state the foregoing without disparaging the physician's knowledge, expertise, experience, and ready, complete, and forthright answering all of my questions, all of which I felt was very good, but only out of a wish to feel cared-for.
UofU Patient
December 26, 2020
SUGAR HOUSE HEALTH CENTER
Very good appointment with the whole medical team.
UofU Patient
December 17, 2020
SUGAR HOUSE HEALTH CENTER
I waited three months to get in to see this doctor and he spent 5 minutes in the room me. He did not offer an explanation for my diagnosis and treated me as if I am dumb when I asked for a physiological explanation for my diagnosis. I was very unimpressed with him and his bedside manner.
UofU Patient
December 12, 2020
SUGAR HOUSE HEALTH CENTER
What a kind dr
UofU Patient
November 25, 2020
SUGAR HOUSE HEALTH CENTER
I felt Dr. Rogers was attentive and explained how he came to the conclusions he had about my condition. He listened to concerns I had and addressed them. It was very professional.
UofU Patient
November 21, 2020
SUGAR HOUSE HEALTH CENTER
I wasn't impressed with Dr. Rodgers. 90% of the visit was conducted by his nurse practitioner. When he finally did come in, he was in the room for less than 5 minutes and basically said I agree with what my NP said, see you in a year.
UofU Patient
November 15, 2020
SUGAR HOUSE HEALTH CENTER
we travel from Nevada to Utah because the level of care is second to none.
UofU Patient
November 14, 2020
SUGAR HOUSE HEALTH CENTER
Met first with EMT, (Katie) working as a Medical Assistant. She collected info. Then with Emily, I believe she was a nurse. She drew blood and asked more clarifying questions about the clotting events (DVT and an earlier PE). She showed concern about getting the facts right. Then finally, met with Dr. Rodgers. All of them showed concern and answered my questions effectively. I am grateful to have been cared for by them as a team.
UofU Patient
August 23, 2020
SUGAR HOUSE HEALTH CENTER
They where helpful and did a follow up call a few days later made me feel cared for. Really like dealing with The University health system
UofU Patient
July 31, 2020
SUGAR HOUSE HEALTH CENTER
overall wonderful experience
UofU Patient
May 22, 2020
SUGAR HOUSE HEALTH CENTER
It was a virtual appointment, so not everything could be addressed.
UofU Patient
December 20, 2019
SUGAR HOUSE HEALTH CENTER
They were very he, also very kind
UofU Patient
December 06, 2019
SUGAR HOUSE HEALTH CENTER
Very good
UofU Patient
November 07, 2019
HUNTSMAN CANCER CENTER
The PA, Emily Armstrong, was really helpful and listened well. She has followed up with me multiple times after my appointment which I really appreciate! Dr. Rogers was excellent and explained things very well to me.
George M. Rodgers, M.D., Ph.D. is a Professor of Medicine in the Division of Hematology and Hematologic Malignancies, Department of Internal Medicine at the University of Utah School of Medicine. He also holds an appointment as an adjunct Professor in the Department of Pathology. He started at the University of Utah in 1988. He is the senior adult hemophilia and thrombosis expert in the state of Utah, and also serves as the adult hemophilia expert for - and receives referrals and consultations from - a six state region. His clinical practice is conducted at the University of Utah's Sugarhouse Clinic. Dr. Rodgers is also a Medical Director for the Coagulation Laboratory at ARUP Laboratories. He is the chairman of the University Hospital Adverse Drug Reaction Subcommittee. He is also a member of the University Hospital Pharmacy & Therapeutics, Department of Medicine Tenure 5-Year Review and the Heme-Onc Fellowship and Clinical Competency Committees. He is also a principal investigator for three clinical trials and the Director of the Utah Center for Bleeding and Clotting Disorders.
For questions regarding Dr. Rodgers' practice, our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist/New Patient Coordinator at http://www.huntsmancancer.org or (801) 587-4630.
Academic Locations
Huntsman Cancer Hospital
801-585-2626
Research Statement
Dr. Rodgers has a basic science interests in vascular biology regarding endothelialcell regulation of hemostasis and angiogenesis. The role of ADAMTS13 in angiogenesis is currently under investigation.
Clinical interests include clinical rials in benign hematology (ITP, TTP, venous thrmobosis, hemophilia, and von Willebrands disease). An investigaor-initiated clinical trial of eltrombopag in aplastic anemia is currently recruiting patients from around the country.
Dr. Rodgers is chair of the NCCN Anemia Panel and an editor (Coagulation) for Wintrobe's Clinical Hematology textbook.
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Professor Pathology - Adjunct Professor |
| Academic Divisions | Clinical Pathology Hematology/BMT |
| Board Certification | American Board of Internal Medicine (Internal Medicine) American Board of Internal Medicine (Sub: Hematology) American Board of Pathology (Sub: Hematology) Federal Licensing Examination National Board of Medical Examiners |
Research Interests
- Physiological Regulation of Hemostasis
- Procoagulant Activities of Vascular Endothelium
- Role of Coagulation in Arteriosclerosis
- Antithrombotic Therapy
- Thrombotic Microangiopathies
Education History
| Fellowship | University of California San Francisco Hematology/Oncology Fellow, 1982 |
| Residency | Baylor College of Medicine Internal Medicine Resident, 1979 |
| Internship | Baylor College of Medicine Intern, 1977 |
| Professional Medical | Tulane University Medicine M.D., 1976 |
| Doctoral Training | Tulane University Pharmacology Ph.D., 1974 |
| Undergraduate | Louisiana State University Biochemistry B.S., 1970 |
Selected Publications - Journal Articles
Journal Article
- Lim MY, Wei G, Presson AP, Bray P, Rodgers GM (2020). High prevalence of overweight/obesity in adult persons with hemophilia in Utah and a review of the literature. Blood Coagul Fibrinolysis, 31(8), 522-529.
- Gilreath JA, Rodgers GM (2019). How I treat cancer-associated anemia. Blood, 136(7), 801-813.
- Williams LB, Javed A, Sabri A, Morgan DJ, Huff CD, Grigg JR, Heng XT, Khng AJ, Hollink IHIM, Morrison MA, Owen LA, Anderson K, Kinard K, Greenlees R, Novacic D, Nida Sen H, Zein WM, Rodgers GM, Vitale AT, Haider NB, Hillmer AM, Ng PC, Shankaracharya, Cheng A, Zheng L, Gillies MC, van Slegtenhorst M, van Hagen PM, Missotten TOAR, Farley GL, Polo M, Malatack J, Curtin J, Martin F, Arbuckle S, Alexander SI, Chircop M, Davila S, Digre KB, Jamieson RV, DeAngelis MM (2019). ALPK1 missense pathogenic variant in five families leads to ROSAH syndrome, an ocular multisystem autosomal dominant disorder. Genet Med, 21(9), 2103-2115.
- Aapro M, Gascn P, Patel K, Rodgers GM, Fung S, Arantes LH Jr, Wish J (2019). Erythropoiesis-Stimulating Agents in the Management of Anemia in Chronic Kidney Disease or Cancer: A Historical Perspective. Front Pharmacol, 9, 1498.
- Lip GY, Halperin JL, Petersen P, Rodgers GM, Pall D, Renfurm RW (2015). A Phase II, double-blind, randomized, parallel group, dose-finding study of the safety and tolerability of darexaban compared with warfarin in patients with non-valvular atrial fibrillation: the oral factor Xa inhibitor for prophylaxis of stroke in atrial fibrillation study 2 (OPAL-2). J Thromb Haemost, 13(8), 1405-13.
- Lee M, Keener J, Xiao J, Long Zheng X, Rodgers GM (2015). ADAMTS13 and its variants promote angiogenesis via upregulation of VEGF and VEGFR2. Cell Mol Life Sci, 72(2), 349-56.
- Gilreath JA, Stenehjem DD, Rodgers GM (2014). Diagnosis and treatment of cancer-related anemia. Am J Hematol, 89(2), 203-12.
- Heikal NM, Murphy KK, Crist RA, Wilson AR, Rodgers GM, Smock KJ (2013). Elevated factor IX activity is associated with an increased odds ratio for both arterial and venous thrombotic events. Am J Clin Pathol, 140(5), 680-5.
- Shirts BH, Rodgers GM, Smock KJ (2012). Prothrombin time, activated partial thromboplastin time and dilute Russell's Viper Venom times are not shorter in patients with the prothrombin G20210A mutation, and dilute Russell's Viper Venom time may be longer. Thromb Res, 130(3), e134-8.
- Lee M, Rodansky ES, Smith JK, Rodgers GM (2012). ADAMTS13 promotes angiogenesis and modulates VEGF-induced angiogenesis. Microvasc Res, 84(2), 109-15.
- Sangle NA, Rodgers GM, Smock KJ (2011). Prevalence of heparin in samples submitted for lupus anticoagulant testing. Lab Hematol, 17(1), 6-11.
- Bentley MJ, Lehman CM, Blaylock RC, Wilson AR, Rodgers GM (2010). The utility of patient characteristics in predicting severe ADAMTS13 deficiency and response to plasma exchange. Transfusion, 50(8), 1654-64.
- Smock KJ, Rodgers GM (2010). Laboratory evaluation of aspirin responsiveness. Am J Hematol, 85(5), 358-60.
- Smock KJ, Crist RA, Hansen SJ, Rodgers GM, Lehman CM (2010). Discard tubes are not necessary when drawing samples for specialized coagulation testing. Blood Coagul Fibrinolysis, 21(3), 279-82.
- Rondina MT, Wheeler M, Rodgers GM, Draper L, Pendleton RC (2009). Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patients. Thromb Res, 125(3), 220-3.
- Smock KJ, Rodgers GM (2009). Laboratory identification of lupus anticoagulants. Am J Hematol, 84(7), 440-2.
- Crist RA, Gibbs K, Rodgers GM, Smock KJ (2009). Effects of EDTA on routine and specialized coagulation testing and an easy method to distinguish EDTA-treated from citrated plasma samples. Lab Hematol, 15(4), 45-8.
- Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK (1992). [Pre-eclampsia: a disorders of the endothelial cells?]. Gynakologe, 25(1), 2-6.
- Rodgers GM, Barrera E Jr, Martin RR (1980). Bacillus cereus bacteremia and hemolytic anemia in a patient with hemoglobin SC disease. Arch Intern Med, 140(8), 1103-4.
- George WJ, Rodgers GM, White LA (1978). Cyclic nucleotides as regulators of erythrocyte proliferation. Adv Cyclic Nucleotide Res, 9, 517-32.
Book
- Bennett ST, Lehman CM, Rodgers GM (2014). Laboratory Hemostasis: A Practical Guide For Pathologists (2nd Edition). New York: Springer.
Edited Book
- Greer JP, Arber DA, Glader BE, List A, Means RT, Paraskevas F, Rodgers GM (Eds.) (2014). Wintrobe's Clinical Hematology - 13th Edition. (13th ed.). Philadelphia: Lippincott Williams & Wilkins.
Book Chapter
- Shami PJ, Rodgers GM (2014). Chapter 19, Endothelium: angiogenesis and the regulation of hemostasis. In Wintrobe's Clinical Hematology (13th, pp. 498–507). Philadelphia: Lippincott Williams and Wilkins.
- Rodgers GM, Lehman CM (2014). Chapter 45, Diagnostic approach to the bleeding disorders. In Wintrobe's Clinical Hematology (13th, pp. 1043-1057). Philadelphia: Lippincott Williams & Wilkins.
- Rodgers GM (2014). Chapter 46, Thrombocytopenia: pathophysiology and classification. In Wintrobe's Clinical Hematology (13th, pp. 1058-1060). Philadelphia: Lippincott Williams & Wilkins.
- Agarwal AM, Rodgers GM (2014). Chapter 49, Miscellaneous causes of thrombocytopenia. In Wintrobe's Clinical Hematology (13th, pp. 1097-1105). Philadelphia: Lippincott Williams & Wilkins.
- Rodgers GM, Rees MM (2014). Chapter 50, Bleeding disorders caused by vascular abnormalities. In Wintrobe's Clinical Hematology (13th, pp. 1106-1121). Philadelphia: Lippincott Williams & Wilkins.
- Powell JS, Rodgers GM (2014). Chapter 53, Inherited coagulation disorders. In Wintrobe's Clinical Hematology (13th, pp. 1143-1185). Philadelphia: Lippincott Williams & Wilkins.
- Rodgers GM (2014). Chapter 54, Acquired coagulation disorders. In Wintrobe's Clinical Hematology (13th, pp. 1186-1217). Philadelphia: Lippincott Williams & Wilkins.
- Pendleton RC, Rodgers GM (2014). Chapter 55, Thrombosis and antithrombotic therapy. In Wintrobe's Clinical Hematology (13th, pp. 1218-1257). Philadelphia: Lippincott Williams & Wilkins.
- Rodgers GM, Means RT (2014). Chapter 51, Thrombocytosis and essential thrombocythemia. In Wintrobe's Clinical Hematology (13th, pp. 1122-1127). Philadelphia: Lippincott, Williams & Wilkins.
Editorial
- Gilreath JA, Rodgers GM (2014). Current quandaries in cancer-associated anemia. 12(8), 1071-5.
- Crawford J, Rodgers GM (2014). Treatment strategies for myeloid growth factors and intravenous iron: when, what, and how? J Natl Compr Canc Netw, 12(5 Suppl), 821-4.
Letter
- Patel SB, Rodgers GM (2014). Continuous infusion of human plasma-derived von Willebrand factor concentrate as an effective therapy in a patient with acquired von Willebrand disease. [Letter to the editor]. Haemophilia, 20(6), e411-4.
- Win K, Rodgers GM (2014). New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome. [Letter to the editor]. Am J Hematol, 89(10), 1017.
- Rodgers GM (2014). Developmental hemostasis: age-specific differences in the levels of hemostatic proteins: a rebuttal. [Letter to the editor]. J Thromb Haemost, 12(2), 285.
- Rodgers, George M (2014). Age-Specific differences in the Levels of Hemostatic Proteins: A Rebuttal [Letter to the editor]. Thromb Haemost, 12, 258.
Abstract
- Desai DS, Lyon E, Rodgers GM, Jama AJ, Wallentine SL, Smock KJ (2013). Gene sequencing aids in differentiation of von Willebrand disease type 2B from platelet-type vWD [Abstract]. FASEB J, 27(871), 3.
- Lee M, Hoyt C, Rodgers GM (2013). ADAMTS13 expressed in glioblastoma and astrocytoma cells can modulate endothelial cell migration [Abstract]. Blood, 122(21), #2306.